Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

199.59
-0.0300-0.02%
Post-market: 199.590.00000.00%16:10 EDT
Volume:221.95K
Turnover:44.22M
Market Cap:3.98B
PE:32.56
High:201.42
Open:197.54
Low:194.67
Close:199.62
52wk High:227.92
52wk Low:93.58
Shares:19.94M
Float Shares:19.46M
Volume Ratio:0.96
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.13
EPS(LYR):6.13
ROE:13.47%
ROA:2.36%
PB:3.91
PE(LYR):32.56

Loading ...

Ligand Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $270

THOMSON REUTERS
·
Dec 09, 2025

Ligand Pharmaceuticals Director John W. Kozarich Reports Sale of Common Shares

Reuters
·
Dec 04, 2025

Will Lower Short Interest Reshape Ligand Pharmaceuticals' (LGND) Sentiment Among Industry Peers?

Simply Wall St.
·
Dec 01, 2025

Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says

MT Newswires Live
·
Nov 26, 2025

Ligand Pharma (LGND) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 25, 2025

Ligand Pharmaceuticals Q3 EPS USD 5.68

Reuters
·
Nov 20, 2025

Ligand Pharmaceuticals Director Nancy Ryan Gray Reports Disposal of Common Shares

Reuters
·
Nov 13, 2025

Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth

TIPRANKS
·
Nov 11, 2025

Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
Nov 11, 2025

RBC Raises Price Target on Ligand Pharmaceuticals to $234 From $185, Keeps Outperform Rating

MT Newswires Live
·
Nov 10, 2025

November 2025's Top Stocks Priced Below Estimated Value

Simply Wall St.
·
Nov 08, 2025

Ligand Pharmaceuticals, Inc. : Oppenheimer Raises Target Price to $275 From $250

THOMSON REUTERS
·
Nov 07, 2025

Benchmark Co. Sticks to Its Buy Rating for Ligand Pharma (LGND)

TIPRANKS
·
Nov 07, 2025

Ligand Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 07, 2025

Ligand price target raised to $231 from $206 at H.C. Wainwright

TIPRANKS
·
Nov 07, 2025

Stock Track | Ligand Pharmaceuticals Soars 5.91% Pre-Market on Strong Q3 Results and Raised Guidance

Stock Track
·
Nov 07, 2025

Ligand Pharma Q3 revenue jumps; raises 2025 guidance

Reuters
·
Nov 06, 2025

Ligand Pharmaceuticals Q3 Adj. EPS $3.09 Beats $1.92 Estimate, Sales $115.461M Beat $58.795M Estimate

Benzinga
·
Nov 06, 2025

BRIEF-Ligand Pharmaceuticals Q3 EPS USD 5.68

Reuters
·
Nov 06, 2025

Ligand Pharmaceuticals 2025 FY Adj EPS $7.40 - $7.65

THOMSON REUTERS
·
Nov 06, 2025